Ketobemidone
| Clinical data | |
|---|---|
| Trade names | Ketogan | 
| Other names | Ketobemidone, Cliradon, Cymidon, Ketogan, Ketorax | 
| AHFS/Drugs.com | International Drug Names | 
| Routes of administration | By mouth, rectal, intravenous | 
| ATC code | |
| Legal status | |
| Legal status | 
 | 
| Pharmacokinetic data | |
| Bioavailability | 34~40% (oral), 44% (rectal) | 
| Elimination half-life | 2–4 hours | 
| Duration of action | 3–5 hours | 
| Identifiers | |
| 
 | |
| CAS Number | |
| PubChem CID | |
| DrugBank | |
| ChemSpider | |
| UNII | |
| KEGG | |
| ChEMBL | |
| CompTox Dashboard (EPA) | |
| ECHA InfoCard | 100.006.748 | 
| Chemical and physical data | |
| Formula | C15H21NO2 | 
| Molar mass | 247.338 g·mol−1 | 
| 3D model (JSmol) | |
| 
 | |
| 
 | |
| (what is this?) (verify) | |
Ketobemidone, sold under the brand name Ketogan (a mixture of ketobemidone and Spasmolytic A29) among others, is a powerful synthetic opioid painkiller. Its effectiveness against pain is in the same range as morphine, and it also has some NMDA-antagonist properties imparted, in part, by its metabolite norketobemidone. This may make it useful for some types of pain that do not respond well to other opioids. It is marketed in Denmark, Iceland, Norway. Until 2024 it was available in, but is now withdrawn in Sweden. It is used for severe pain.